Group 1: Company Overview - Medtronic plc (NYSE:MDT) is one of the world's largest medical device makers, with a diverse portfolio in diabetes care, cardiovascular health, medical surgical, and neuroscience [3] - The company has been rewarding shareholders with growing dividends for 48 years, currently paying a quarterly dividend of $0.71 per share, resulting in a dividend yield of 3.01% as of September 26 [5] Group 2: Market Position and Growth Potential - Medtronic is well-positioned for long-term growth, benefiting from its strong industry presence and the global trend of an aging population [4] - The company has invested in high-potential areas such as robotic-assisted surgery, noting that fewer than 5% of eligible surgeries are currently performed robotically, indicating significant growth opportunities [4] Group 3: Resilience in Economic Downturns - In a recession, defensive sectors like healthcare tend to perform better, and Medtronic is expected to benefit from this resilience due to the essential nature of its medical products and services [2]

Accessibility StatementSkip Navigation GALWAY, Ireland, Sept. 29, 2025 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public offering (the "Offering") of €750,000,000 principal amount of 2.950% senior notes due 2030 and €750,000,000 principal amount of 4.200% senior notes due 2045 (collectively, the "Notes"). All of Medtronic, Inc.'s obligations under the Notes are fully and unconditionally guarant ...

Core Insights - The article discusses the advancements and market potential of spinal surgery robots, highlighting their role in enhancing surgical precision and safety through integrated technologies [1][16]. Market Overview - The global spinal surgery robot market is projected to reach $900 million by 2031, with a compound annual growth rate (CAGR) of 19.6% in the coming years [1]. - The leading manufacturers in the spinal surgery robot market include Medtronic, Globus Medical, Zimmer Biomet, Tianzhihang, and Brainlab, with the top four companies holding approximately 94.0% of the market share in 2024 [5]. Product Segmentation - Guided surgical robots dominate the market, accounting for about 99.0% of the total market share [8]. - Minimally invasive surgery is the largest application segment, representing approximately 80.7% of the demand [10]. Market Drivers - Key drivers for the spinal surgery robot market include technological innovation, increasing clinical demand, and the ongoing digital transformation in the healthcare sector [16]. - The aging global population and the rise in spinal degenerative diseases are contributing to the growing need for precise and minimally invasive surgical solutions [16]. Challenges - The market faces challenges such as high equipment procurement and maintenance costs, which create economic pressure on smaller hospitals [17]. - There is a need for extensive training and integration with existing imaging and navigation systems, which can hinder adoption in underdeveloped regions [17]. Future Trends - The spinal surgery robot industry is expected to accelerate towards greater intelligence, integration, and minimally invasive techniques [18]. - Future robots will likely incorporate advanced technologies such as AI, big data, and machine vision for improved decision-making and surgical planning [18].

I am convinced that Medtronic (NYSE: MDT ) shares are undervalued right now and represent an attractive buying opportunity. The company is showing steady growth: the last quarter was already the 11th consecutive quarter withHi there! I’m Narek, and I’ve been in the investment world for over six years. I started out as an equity analyst at European banks, digging into reports and learning how to spot value in the markets. I’ve worked across sectors — from telecom to industry — and found that behind every fin ...

Core Viewpoint - Medtronic has appointed Dr. Adam S. Arthur as the new Chief Medical Officer for its Neurovascular business, effective September 30, 2025, aiming to enhance clinical leadership and drive innovation in the company's product pipeline and market expansion [1][6]. Group 1: Leadership Appointment - Dr. Arthur is a recognized clinical expert in the neurovascular field with over 20 years of experience, having completed his medical education at the University of Virginia and specialized training at the University of Utah and Semmes Murphey Clinic [2][4]. - His clinical focus includes complex diseases such as brain aneurysms and strokes, and he has led several international multicenter studies, contributing significantly to the field of endovascular treatment [4][5]. Group 2: Strategic Intent - The appointment of Dr. Arthur is seen as a strategic move to strengthen Medtronic's clinical insights and accelerate the translation of research into clinical practice, enhancing patient outcomes [6][19]. - Linnea Burman, President of Medtronic Neurovascular, emphasized that Dr. Arthur's expertise will help shape the future of stroke care and improve global patient access to advanced neurovascular treatments [6]. Group 3: Industry Context and Future Outlook - The neurovascular intervention market is rapidly growing, projected to exceed $20 billion by 2030, driven by an aging population and the increasing prevalence of cardiovascular diseases [7]. - Medtronic aims to solidify its industry position through ongoing pipeline investments and leadership optimization, with the Neurovascular segment expected to be a key growth driver in the coming years [7][11]. Group 4: Financial Performance and Growth Expectations - In Q1 of FY2025, Medtronic reported total revenue of $8.578 billion, with the Neurovascular segment generating $2.416 billion, reflecting a year-over-year growth of 4.3% [11]. - The company anticipates that advancements in carotid stenting and hemorrhagic stroke treatment products will significantly boost the performance of the Neurovascular business in the upcoming quarters [11]. Group 5: Product Line Overview - Medtronic Neurovascular's product portfolio encompasses a comprehensive stroke treatment chain, including carotid stenting, hemorrhagic stroke treatment, endovascular devices, and imaging systems [12][14][15][16][17]. - This integrated approach positions Medtronic as a major player in the global stroke treatment market, addressing the critical need for effective and safe vascular intervention devices [18].

Group 1 - The company is experiencing a potential inflection point in growth rate, with expectations for acceleration in the second half of the year [1][2] - The new Executive VP & CFO believes that his automotive background can contribute incremental value to the company's performance [2] - Specific growth opportunities have been identified in areas such as cardiac ablation and other business segments [1]

Medtronic 2025 Conference Summary Company Overview - **Company**: Medtronic (NYSE: MDT) - **Date**: September 24, 2025 Key Industry Insights - **Growth Opportunities**: Medtronic is positioned for an inflection in growth, particularly in areas such as Cardiac Ablation, Ardian, and HUGO [3][4] - **Market Leadership Ambition**: The company aims to become the number one player in the electrophysiology (EP) market, leveraging strong product demand and upcoming innovations [63] Core Financial Insights - **EPS Growth Commitment**: Medtronic is targeting high single-digit EPS growth for the upcoming year, with a clear path to achieve this based on internal assessments [6][7] - **Gross Margin Recovery**: The company aims to recover gross margins to pre-COVID levels, currently about 380 basis points lower than before the pandemic [12][8] - **Operational Improvements**: Significant improvements in pricing and cost management are expected to contribute to gross margin recovery, with a target of 1% to 1.5% annual net cost reductions [14][15] Strategic Focus Areas - **Innovation Reinvestment**: Medtronic plans to reinvest a portion of the benefits from growth into innovation through both organic R&D and M&A activities [4][10] - **M&A Strategy**: The company is looking to pursue tuck-in acquisitions in the range of €1 billion to €4 billion, focusing on companies just before or after commercialization [51][52] - **Free Cash Flow Generation**: Medtronic generates over €5 billion in free cash flow and aims to improve this through better operating margins and working capital management [59][61] Operational Enhancements - **Supply Chain Optimization**: The company is working on reducing the number of suppliers and SKU reduction to enhance operational efficiency [33][34] - **Digital Surgery and HUGO**: The HUGO platform is expected to create a comprehensive ecosystem for surgical procedures, enhancing margins and competitiveness [68][69] Market Dynamics - **Cardiac Ablation and RDN**: The company sees significant potential in the RDN market, with a large patient base and expected rapid commercialization [72][73] - **Diabetes Business Divestiture**: Medtronic is in the process of divesting its diabetes business, which is expected to alleviate margin pressures [15][16] Governance and Shareholder Engagement - **Board Enhancements**: Following engagement with Elliott Management, Medtronic has added medtech expertise to its board and established dedicated committees for growth and operations [40][41] - **Shareholder Value Focus**: The company is committed to improving shareholder value through disciplined execution and strategic investments [49][50] Conclusion - Medtronic is strategically positioned for growth with a focus on innovation, operational efficiency, and shareholder value enhancement. The company is committed to recovering gross margins, achieving high EPS growth, and leveraging M&A opportunities to drive future success.

Core Insights - Medtronic plc (MDT) has received FDA approval for the Altaviva device, a minimally invasive implantable tibial neuromodulation therapy aimed at treating urge urinary incontinence, marking a significant advancement in bladder control therapies [1][9] - The introduction of the Altaviva device positions MDT as the only company with a comprehensive portfolio of neuromodulation therapies for bladder control symptoms, which is expected to enhance revenue growth and improve stock performance [3][4] Company Developments - The Altaviva device features a 15-year battery life, quick recharging capabilities, and is MRI-compatible, making it a patient-friendly option for those suffering from urge urinary incontinence [6][9] - Medtronic's market capitalization stands at $121.80 billion, with a projected revenue growth of 6.8% for fiscal 2026 compared to fiscal 2025 [4] - The company has consistently outperformed earnings expectations in the past four quarters, with an average surprise of 2.20% [4] Industry Context - Bladder control issues affect approximately 43 million U.S. adults, with nearly 16 million experiencing urge urinary incontinence, indicating a substantial market for the Altaviva device [10] - The global urinary incontinence therapeutics market is expected to grow at a CAGR of 4.0% from 2024 to 2030, driven by an aging population and increased awareness [10]

Core Viewpoint - Medtronic's ADAPT-PD trial results demonstrate the safety and efficacy of the BrainSense™ adaptive deep brain stimulation (aDBS) system for treating Parkinson's Disease, marking a significant advancement in personalized neurostimulation therapy [1][22]. Clinical Trial Results (ADAPT-PD) - The ADAPT-PD study is a multi-center, prospective, single-blind, randomized crossover trial initiated in 2021, involving 68 primary cohort patients and 17 directional stimulation cohort patients across 10 research centers in the US, Canada, and Europe [2]. - Two adaptive algorithm modes were tested: Single Threshold mode, which adjusts stimulation intensity rapidly within 250 milliseconds, and Dual Threshold mode, which changes stimulation intensity gradually over several minutes [4]. Key Results - Under the Dual Threshold aDBS mode, patients experienced an average increase of approximately 1.3 hours in daily ON time and a reduction of about 1.6 hours in OFF time; when using a self-selected aDBS mode, ON time increased by about 1.4 hours and OFF time decreased by 1.7 hours [7]. - The primary endpoint showed that 91% of patients in the Dual Threshold mode achieved equivalence in "ON time without troublesome dyskinesia" compared to traditional continuous DBS, while the Single Threshold mode had a success rate of 79% [10]. Product Technical Features (BrainSense™ aDBS System) - The BrainSense™ aDBS system features a closed-loop design that allows real-time monitoring of brain activity and automatic adjustment of stimulation parameters, enhancing treatment personalization and reducing the need for frequent manual adjustments [15]. - Energy efficiency was noted, with the Single Threshold aDBS mode showing an average reduction of about 15% in total energy consumption compared to continuous DBS, indicating potential for extended battery life [16]. Clinical Evidence - The clinical validation of the BrainSense™ aDBS system has progressed through a series of studies, culminating in the publication of the ADAPT-PD trial results in JAMA Neurology, confirming the efficacy and safety of the aDBS technology [22][23]. Impact on Parkinson's Disease Treatment - The introduction of the BrainSense™ aDBS system addresses the limitations of traditional DBS, which often requires frequent adjustments due to its continuous stimulation approach, thereby improving patient quality of life [24][26]. - The results from the ADAPT-PD trial signify a transformative shift in treatment modalities from continuous stimulation to intelligent, personalized, and dynamic interventions, potentially setting a new standard for precision neurotherapy [26].

Group 1 - Medtronic has a historically high dividend yield of around 3% and is working on improving its business performance, which could make it a strong healthcare stock to consider [1] - The company has faced challenges due to a development dry spell but is now gaining traction with new surgical robots and cardiac ablation systems [2] - Medtronic is focusing on its most profitable businesses, with a significant move being the spinoff of its diabetes treatment division, which is expected to be immediately accretive to earnings [3] Group 2 - As new products are introduced, Medtronic's earnings growth may exceed Wall Street's expectations, driven by higher profit margins and increased revenues from R&D developments [4] - The current high yield provides an opportunity for investors to benefit while waiting for the market to recognize the improving fundamentals of Medtronic's business [4] - Medtronic's growth has stalled in recent years, but the company is actively bringing new products to market and focusing on its most profitable segments [6]